标题
Predictive biomarkers investigated in glioblastoma
作者
关键词
-
出版物
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 14, Issue 7, Pages 883-893
出版商
Informa UK Limited
发表日期
2014-08-06
DOI
10.1586/14737159.2014.945436
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- MGMT promoter methylation in plasma of glioma patients receiving temozolomide
- (2014) Valentina Fiano et al. JOURNAL OF NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
- (2013) E. Galanis et al. CLINICAL CANCER RESEARCH
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- (2013) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
- (2013) Oscar Gallego et al. JOURNAL OF NEURO-ONCOLOGY
- Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome
- (2013) Shadi Lalezari et al. NEURO-ONCOLOGY
- Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma
- (2013) Emeline Tabouret et al. NEURO-ONCOLOGY
- A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)
- (2013) Markus Hutterer et al. NEURO-ONCOLOGY
- Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
- (2013) Lucia Cuppini et al. PLoS One
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
- (2013) T. T. Batchelor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
- (2012) Pierre Bady et al. ACTA NEUROPATHOLOGICA
- Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g
- (2012) Véronique Quillien et al. CANCER
- RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients
- (2012) Arnab Chakravarti et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
- (2012) Gregory Cairncross et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
- (2012) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression
- (2012) W. Zhang et al. NEURO-ONCOLOGY
- Patupilone (Epothilone B) for Recurrent Glioblastoma: Clinical Outcome and Translational Analysis of a Single-Institution Phase I/II Trial
- (2012) Christoph Oehler et al. ONCOLOGY
- Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients
- (2012) Brendan Fong et al. PLoS One
- A Simplified Approach for the Molecular Classification of Glioblastomas
- (2012) Marie Le Mercier et al. PLoS One
- Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept
- (2011) J. F. de Groot et al. CLINICAL CANCER RESEARCH
- Predictive impact of MGMT promoter methylation in glioblastoma of the elderly
- (2011) Guido Reifenberger et al. INTERNATIONAL JOURNAL OF CANCER
- Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
- (2011) John F. de Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
- (2011) Jaime Gállego Pérez-Larraya et al. JOURNAL OF CLINICAL ONCOLOGY
- MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?
- (2011) Alessandro Della Puppa et al. JOURNAL OF NEURO-ONCOLOGY
- MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma
- (2011) A. L. Rivera et al. NEURO-ONCOLOGY
- O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients
- (2011) S. Spiegl-Kreinecker et al. NEURO-ONCOLOGY
- A multigene predictor of outcome in glioblastoma
- (2011) H. Colman et al. NEURO-ONCOLOGY
- Phase I trial of vorinostat combined with bevacizumab and CPT-11 in recurrent glioblastoma
- (2011) Prakash Chinnaiyan et al. NEURO-ONCOLOGY
- Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
- (2011) N. Butowski et al. NEURO-ONCOLOGY
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM
- (2011) Nameeta Shah et al. PLoS One
- A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas
- (2010) Jeffrey J. Raizer et al. CANCER
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
- (2010) Houtan Noushmehr et al. CANCER CELL
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Rationally Designed Pharmacogenomic Treatment Using Concurrent Capecitabine and Radiotherapy for Glioblastoma; Gene Expression Profiles Associated with Outcome
- (2010) J. M. Grunda et al. CLINICAL CANCER RESEARCH
- O 6-Methylguanine DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression is correlated with progression-free survival in patients with glioblastoma
- (2010) Yukihiko Sonoda et al. International Journal of Clinical Oncology
- Phase II Evaluation of Gefitinib in Patients With Newly Diagnosed Grade 4 Astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074
- (2010) Joon H. Uhm et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
- (2010) John H. Sampson et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
- (2010) Tracy T. Batchelor et al. JOURNAL OF CLINICAL ONCOLOGY
- Predominant influence of MGMT methylation in non-resectable glioblastoma after radiotherapy plus temozolomide
- (2010) N. Thon et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients
- (2010) François Ducray et al. Molecular Cancer
- MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients
- (2010) O. Slaby et al. NEOPLASMA
- Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
- (2010) W. K. A. Yung et al. NEURO-ONCOLOGY
- Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
- (2009) B. Neyns et al. ANNALS OF ONCOLOGY
- A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
- (2009) A. Gregory Sorensen et al. CANCER RESEARCH
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
- (2009) David A. Reardon et al. JOURNAL OF NEURO-ONCOLOGY
- MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
- (2009) E. R. Gerstner et al. NEUROLOGY
- Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan
- (2008) Sith Sathornsumetee et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177
- (2008) Paul D. Brown et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
- (2008) Michael D. Prados et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
- (2008) J. F. de Groot et al. JOURNAL OF NEURO-ONCOLOGY
- A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
- (2008) Teri N. Kreisl et al. JOURNAL OF NEURO-ONCOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started